Profilo
Heng Hsin Tang served as a Non-Executive Director at TBG Diagnostics Ltd.
from 2014 to 2015 and as the Managing Director at PharmaSynth Pty Ltd.
in 2014-2015.
Mr. Tang received an undergraduate degree and an MBA from The University of Queensland.
Precedenti posizioni note di Heng Hsin Tang
| Società | Posizione | Fine |
|---|---|---|
| TBG DIAGNOSTICS LIMITED | Amministratore Delegato | 28/07/2014 |
PharmaSynth Pty Ltd.
 PharmaSynth Pty Ltd. Pharmaceuticals: MajorHealth Technology PharmaSynth Pty Ltd. develops drugs and provides contract manufacturing services. The firm’s services include biopharmaceutical contract manufacturing, GMP manufacture of recombinant proteins and vaccines, microbial products, small molecule synthesis for human and veterinary use, synthetic organic chemistry, production of GMP material for pre-clinical studies and clinical trial material batches for Phase 1, 2 and 3 clinical studies. The company was founded in 2009 and is headquartered in Darra, Australia. | Amministratore Delegato | 16/03/2015 |
Formazione di Heng Hsin Tang
| The University of Queensland | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
TBG Diagnostics Ltd.
 TBG Diagnostics Ltd. Pharmaceuticals: MajorHealth Technology TBG Diagnostics Ltd. engages in the research, development, and manufacture of biopharmaceuticals. It operates through the InVitro Diagnostics segment, which involves in the research of biological drugs and the retail and wholesale of veterinary drugs. The company was founded on September 26, 1989 and is headquartered in Melbourne, Australia. | Health Technology |
PharmaSynth Pty Ltd.
PharmaSynth Pty Ltd. Pharmaceuticals: MajorHealth Technology PharmaSynth Pty Ltd. develops drugs and provides contract manufacturing services. The firm’s services include biopharmaceutical contract manufacturing, GMP manufacture of recombinant proteins and vaccines, microbial products, small molecule synthesis for human and veterinary use, synthetic organic chemistry, production of GMP material for pre-clinical studies and clinical trial material batches for Phase 1, 2 and 3 clinical studies. The company was founded in 2009 and is headquartered in Darra, Australia. | Health Technology |
- Borsa valori
- Insiders
- Heng Hsin Tang
